- Home
- JAGX vs MYNZ Comparison
JAGX vs MYNZ Comparison
Compare JAGX & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- MYNZ
- Stock Information
- Founded
- JAGX 2013
- MYNZ 2021
- Country
- JAGX United States
- MYNZ Germany
- Employees
- JAGX N/A
- MYNZ N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- MYNZ Health Care
- Exchange
- JAGX Nasdaq
- MYNZ Nasdaq
- Market Cap
- JAGX 3.5M
- MYNZ 5.5M
- IPO Year
- JAGX N/A
- MYNZ 2021
- Fundamental
- Price
- JAGX $2.39
- MYNZ $1.80
- Analyst Decision
- JAGX Strong Buy
- MYNZ Buy
- Analyst Count
- JAGX 1
- MYNZ 2
- Target Price
- JAGX $60.00
- MYNZ $14.00
- AVG Volume (30 Days)
- JAGX 98.7K
- MYNZ 154.7K
- Earning Date
- JAGX 08-12-2025
- MYNZ 07-22-2025
- Dividend Yield
- JAGX N/A
- MYNZ N/A
- EPS Growth
- JAGX N/A
- MYNZ N/A
- EPS
- JAGX N/A
- MYNZ N/A
- Revenue
- JAGX $11,552,000.00
- MYNZ $893,991.00
- Revenue This Year
- JAGX $22.41
- MYNZ $26.06
- Revenue Next Year
- JAGX $30.00
- MYNZ $4.97
- P/E Ratio
- JAGX N/A
- MYNZ N/A
- Revenue Growth
- JAGX 13.93
- MYNZ N/A
- 52 Week Low
- JAGX $2.28
- MYNZ $1.34
- 52 Week High
- JAGX $110.75
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- JAGX 29.08
- MYNZ 57.87
- Support Level
- JAGX $2.53
- MYNZ $1.35
- Resistance Level
- JAGX $2.79
- MYNZ $2.15
- Average True Range (ATR)
- JAGX 0.20
- MYNZ 0.13
- MACD
- JAGX 0.12
- MYNZ 0.10
- Stochastic Oscillator
- JAGX 8.96
- MYNZ 71.67
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.